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Abstract
We tested the hypothesis that down-regulated hearts, as observed during low-flow ischemia, adapt better to low O
2
 supply than
non-down-regulated, or hypoxic, hearts. To address the link between down-regulation and endogenous ischemic protection,
we compared myocardial tolerance to ischemia and hypoxia of increasing duration. To that end, we exposed buffer-perfused
rat hearts to either low-flow ischemia or hypoxia (same O
2
 shortage) for 20, 40 or 60 min (n = 8/group), followed by reper-
fusion or reoxygenation (20 min, full O
2
 supply). At the end of the O
2
 shortage, the rate·pressure product was less in ischemic
than hypoxic hearts (p < 0.0001). The recovery of the rate·pressure product after reperfusion or reoxygenation was not differ-
ent for t = 20 min, but was better in ischemic than hypoxic hearts for t = 40 and 60 min (p < 0.02 and p < 0.0002, respectively).
The end-diastolic pressure remained unchanged during low-flow ischemia (0.024 ± 0.013 mmHg·min–1), but increased sig-
nificantly during hypoxia (0.334 ± 0.079 mmHg·min–1). We conclude that, while the duration of hypoxia progressively im-
paired the rate·pressure product and the end-diastolic pressure, hearts were insensitive of the duration of low-flow ischemia,
thereby providing evidence that myocardial down-regulation protects hearts from injury. Excessive ATP catabolism during
ischemia in non-down-regulated hearts impaired myocardial recovery regardless of vascular, blood-related and neuro-hormo-
nal factors. These observations support the view that protection is mediated by the maintenance of the ATP pool. (Mol Cell
Biochem 226: 141–151, 2001)
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Abbreviations: DP – developed pressure; EDP – end-diastolic pressure; HR – heart rate; IMP – inosine-5’-monophosphate;
PP – perfusion pressure; RPP – rate·pressure product; TANP – total adenine nucleotides and purines, i.e. the sum of ATP, ADP,
AMP, IMP, adenosine, inosine, hypoxanthine, xanthine and urate; VO
2
 – O
2
 uptake
this injury is the outcome of complex biochemical interac-
tions that antecede, possibly trigger, apoptotic and necrotic
processes [1]. No universal experimental model exists to
fully characterize these phenomena, but the isolated per-
Introduction
A necessary step to recover the ischemic myocardium, re-
perfusion is often associated with injury. It is accepted that
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fused heart, a model free from neuro-hormonal and blood-
related features, has became useful to address the relative
role of some of the paths leading to injury. For example,
comparing low-flow ischemia with hypoxia at the same O
2
supply helped to provide insight into the involved mecha-
nisms. Although originated by different mechanisms, is-
chemia and hypoxia share unmatched O
2 
supply-to-demand
ratio as a common feature. However, the two stresses are
different for many aspects. Of interest in this study, low-flow
ischemia is associated with down-regulation of myocardial
performance, while hypoxia does not elicit down-regulation
[2]. By sparing high-energy phosphates [3] and glycogen
stores [4], down-regulation during O
2 
shortage may in prin-
ciple represent a major mechanism that generates protec-
tion. But no direct observation is available to support this
hypothesis.
Here, we test the hypothesis that down-regulated hearts
may adapt to low O
2 
supply better than non-down-regulated
hearts. We reason that, if down-regulation is not critical to
generate protection, then the post-ischemic functional depres-
sion is expected to be proportional to the duration of the O
2
shortage. In contrast, if down-regulation is crucial, then the
correlation between the functional depression and the dura-
tion of stress should be weak. This speculation refers to the
concept of adaptation: if down-regulated hearts have adapted
to ischemia, possibly by establishing a new equilibrium be-
tween energy supply and energy demand [5], then they would
tolerate the stress better than non-down-regulated hearts. This
issue is investigated in two ways. First, we assessed the re-
covery of hypoxic non-down-regulated and ischemic down-
regulated hearts after variable (20, 40 and 60 min) stress
duration. Second, we assessed whether the availability of ATP
and/or ATP precursors before the reperfusion represents a
limiting factor for the recovery of the ATP pool and hence of
myocardial performance during the reperfusion. For this
purpose, we reanalyzed published data, which were obtained
in the same experimental model, to correlate myocardial bio-
energetics during the O
2
 shortage with the recovery of per-
formance. Of interest, previous reports on this issue, either
in hearts or in muscles, are very conflicting: while some
confirm that hypothesis [6–8], others definitely reject it [9–
12].
We will show that the duration of low-flow ischemia does
not appreciably influence post-ischemic recovery, but the
recovery of post-hypoxic hearts worsens proportionally to the
duration of hypoxia. This observation is consistent with the
hypothesis that down-regulation during the O
2
 shortage can
elicit endogenous protection against low-flow ischemia but
not against hypoxia. This differential behavior can be ex-
plained on the basis of variable tissue contents of ATP and
ATP precursors, which are potential biological markers to
predict post-ischemic recovery.
Materials and methods
Heart perfusion
Eight-week old male outbred Sprague–Dawley rats (Lyon,
France, weight = 268 ± 5 g, mean ± S.E.) were anesthetized
(i.p. heparinized sodium thiopental, 100 mg/kg), and the hearts
immediately (<45 sec) mounted on the perfusion system [13].
A roller pump (Ismatec SA, Labortechnik-Analytik, Glatt-
brugg-Zurich, Switzerland) delivered the medium (Krebs–
Henseleit buffer containing 2.0 mM free Ca2+ and 11 mM
glucose) through a 8 µm pore size, 47 mm diameter filter
(MSI, Westboro, MA, USA), a membrane oxygenator (Di-
deco, Mirandola, Italy), a pre-heater and the aortic cannula.
We used two gas cylinders (Carbagas, Lausanne, Switzer-
land, nominal accuracy ± 0.01%), one at high PO
2
 (94% O
2
and 6% CO
2
), and one at low PO
2 
(10% O
2
, 6% CO
2
, 84%
N
2
). High PO
2
 gas yielded pH = 7.34 ± 0.01, PO
2
 = 636.6 ±
6.1 mmHg, and PCO
2
 = 44.9 ± 0.2 mmHg at 37°C. The low
PO
2
 gas yielded the same pH and PCO
2
, but PO
2
 = 66.7 ±
0.2 mmHg. A latex balloon introduced into the left ventri-
cle was connected to a pressure transducer (MPC-500,
Millar Instruments, Houston, TX, USA) to monitor per-
formance. An additional transducer was inserted above the
aortic cannula to monitor the perfusion pressure. A cannula
was inserted into the pulmonary artery to collect the venous
return and monitor venous pH, PO
2
 (model 5300 Oxygen
Monitor, Yellow Springs, Yellow Springs, OH, USA) and
[lactate] (COBAS FARA II, Hoffman-La Roche, Basel,
Switzerland).
Measurements
The performance was monitored by a LabView system (Na-
tional Instruments, Austin, TX, USA) running on a PC. The
measured parameters included the end-diastolic pressure
(EDP), the heart rate (HR), the developed pressure (DP), the
perfusion pressure (PP), and the O
2
 uptake (VO
2
, calculated
from arterial PO
2
, venous PO
2
 and coronary flow). The prod-
uct DP·HR, i.e. the rate·pressure product (RPP) provided an
integrated index of myocardial performance. The resistance
was calculated as (PP-EDP)/flow per g of ventricle [14]. The
lactate release was calculated from venous [lactate] and coro-
nary flow. The ATP turnover rate was estimated as (lactate
release) + (6·VO
2
) [2], assuming ATP/lactate ratio = 1.0 (glu-
cose as substrate without significant glycogenolysis), ATP/
O
2
 = 6 (no mitochondrial uncoupling), and no ATP produc-
tion from the oxidation of fatty acids and amino acids, which
were absent from the perfusion buffer.
The recovery of performance is expressed as %RPP, with
reference to the value measured at the end of the stabiliza-
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tion period. As the volume of the intraventricular balloon was
established at the start of the perfusion and kept constant
afterwards, any subsequent EDP rise (∆EDP) is associated
to the onset of diastolic contracture.
Experimental protocol
After mounting on the perfusion system, the balloon volume
was adjusted to yield EDP = 10 mmHg. Hearts underwent
baseline perfusion for 30 min (flow = 15 ml/min, PO
2 
~ 636
mmHg). Then, hearts were exposed to either low-flow is-
chemia or hypoxia for variable times (n = 8/group, Fig. 1).
For low-flow ischemia experiments, the coronary flow was
reduced to one-tenth of baseline, i.e. 1.5 ml/min. For hypoxia
experiments, the gas flowing through the oxygenator was
switched to the PO
2 
~ 67 mmHg gas, i.e. one-tenth of base-
line. Therefore, in both cases the O
2
 supply (PO
2
·flow) was
the same, one-tenth of baseline. At the end of the O
2
 shortage,
hearts were reperfused or reoxygenated for 20 min at full O
2
supply, and the performance was compared with that measured
at the end of the stabilization period.
Fig. 1. Diagram of the experimental protocols used in this study. An entire set of performance and metabolic data was obtained at the end of each phase.
Perfusion conditions during stabilization or recovery: pH = 7.34 ± 0.01, arterial PO2 = 636.6 ± 6.1 mmHg, arterial PCO2 = 44.9 ± 0.2 mmHg, flow = 15 ml/
min. Low-flow ischemia: flow = 1.5 ml/min. Hypoxia: arterial PO2 = 66.7 ± 0.2 mmHg.
Table 1. List of previously published data that were reconsidered to assess the link between the tissue content in ATP and ATP precursors during the O
2
shortage, and the recovery after reperfusion or reoxygenation
Intervention Ref. Time (min) Flow (ml/min) PaO2 (mmHg) nischemia nreperfusion
Low-flow ischemia (13) 20 1.5 670 8 8
Hypoxia (13) 20 15 67 7 9
‘Mixed’ hypoxia and low-flow ischemia (13) 20 7.5 140 8 9
Low-flow ischemia (4) 10 1.5 670 4 13
Hypoxia (4) 10 15 67 4 13
Low-flow ischemia (15) 60 1.5 670 4 7
Low-flow ischemia and 10–6M trimetazidine (15) 60 1.5 670 4 7
Low-flow ischemia and pacing (3) 20 1.5 670 7 9
Hypoxia and pacing (3) 20 15 67 7 8
Total 53 83
During stabilization and reperfusion, the flow and the arterial PO2 (PaO2 ) were 15 ml/min and 640–670 mmHg, respectively. The time duration, flow and
PaO2 conditions of the various low-flow ischemia or hypoxia experiments are reported in the table. Abbreviations: nischemia = the number of determinations of
ATP and TANP contents at the end of ischemia; nreperfusion = the number of determinations of performance recovery.
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The investigation conforms to the Guide for the Care and
Use of Laboratory Animals published by the US National
Institutes of Health (NIH Publication No. 85-23, revised
1996).
Reanalysis of published data
For our purposes, we re-analyzed previously published data
(Table 1, n = 4–13 per group) that were obtained using the
same experimental model as that described above, yet under
a variety of conditions that induced performance recoveries
in the 55–95% range [3, 4, 13, 15]. In all the groups, hearts
underwent a 20–30 min stabilization perfusion at full O
2
 sup-
ply to obtain baseline values. Then, hearts were exposed to
either low-flow ischemia or hypoxia for variable times (Table
1). After performance measurement, hearts were either freeze-
clamped (n = 53) or allowed to recover (n = 83). In the first
case, tissue was extracted with 0.5M HClO
4
, neutralized and
assayed by HPLC methods [16] for ATP, phosphocreatine, as
well as total adenine nucleotides and purines (TANP), i.e. the
sum of ATP, ADP, AMP, inosine-5’-monophosphate (IMP), ad-
enosine, inosine, hypoxanthine, xanthine and urate. In the sec-
ond case, hearts were reperfused or reoxygenated for 20–30
Table 2. Myocardial performance at the end of the stabilization period, when
hearts were perfused with full O2 supply
Parameter (unit) Mean ± S.E.
Heart rate (HR), min–1 270  ± 4
End-diastolic pressure (EDP), mmHg 10.2  ± 0.1
Maximal rate of contraction (+dP/dtmax), mmHg/sec 4254  ± 73
Maximal rate of relaxation (–dP/dtmax), mmHg/sec 2266 ± 28
Perfusion pressure (PP), mmHg 75  ± 1
Resistance, mmHg·min/ml/g 3.34 ± 0.65
Developed pressure (DP), mmHg 113  ± 1
Rate·pressure (RPP), mmHg·min–1·10–3 30.3  ± 0.4
Venous PO2 (PvO2), mmHg 237  ± 8
O2 consumption (VO2), µmoles/min 9.1  ± 0.2
Venous [lactate], mM <0.2
Lactate release, µmoles/min <2.0
ATP turnover, µmoles/min 54.6  ± 7.7
Ventricle weight, g 0.98 ± 0.03
Coronary flow = 15 ml/min; arterial PO2 = 636 ± 6 mmHg; n = 56.
Fig. 2. Myocardial performance (n = 8/group) as measured at the end of the O2 shortage (20, 40 or 60 min duration), which is represented by either low-flow
ischemia (filled squares) or hypoxia (empty circles) with matched O2 supply. *Significant differences from low-flow ischemia (p < 0.05, Student’s t-test).
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min under the same conditions of the stabilization, and re-
covery was determined as %RPP and ∆EDP. To correlate the
recovery of performance to the bioenergetic metabolism
during the preceding ischemia or hypoxia, data obtained in
the first group were plotted as independent variables (X-
axis), while data obtained in the second group were plotted
as dependent variables (Y-axis). As each heart was either
freeze-clamped, or allowed to recover, a heart-by-heart analy-
sis is impossible, and the averages of all data obtained under
the same conditions were instead used.
Statistics
Data are expressed as mean ± S.E. When multiple-group
comparison was required, we first performed the one-way
factorial ANOVA test (StatView, Abacus Concepts, Berkeley,
CA, USA). If this test showed significant differences (p <
0.05), the various groups were compared with Fisher’s PLSD
multiple comparison procedure. Statistical correlations were
first tested by ANOVA (StatView, Abacus Concept). If ANOVA
yielded p < 0.05, linear regression lines and regression coef-
ficients were calculated.
To assess the effect of increasing duration of low-flow is-
chemia or hypoxia on myocardial recovery, we performed
regression analysis treating the indices of myocardial perform-
ance recovery, i.e. %RPP or ∆EDP, as the dependent variables,
and the duration of low-flow ischemia or hypoxia as the inde-
pendent variables. To assess the effects of bioenergetics dur-
ing the O
2
 stress on recovery of reperfused or reoxygenated
hearts, the various markers of the myocardial metabolic state
during ischemia were treated as independent variables, while
%RPP or ∆EDP were treated as dependent variables.
Results
The aims of this study required stable and reliable prepara-
tions. In hearts perfused at full O
2
 supply for 110 min, DP,
HR and EDP changed for less than 8.3 ± 4.3 mmHg, 22 ± 10
Fig. 3. Myocardial metabolism (n = 8/group) as measured at the end of the O2 shortage (20, 40 or 60 min duration), which is represented by either low-flow
ischemia (filled squares) or hypoxia (empty circles) with matched O2 supply. *Significant differences from low-flow ischemia (p < 0.05, Student’s t-test).
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min–1 and 1.2 ± 0.9 mmHg, respectively. Table 2 shows the
performance measured at the end of the stabilization period.
Because venous [lactate] was below the detection limit, the
ATP turnover was calculated from VO
2
 only.
Figure 2 shows some parameters related to myocardial
performance, measured at the end of low-flow ischemia or
hypoxia with varying time duration. In hearts exposed to low-
flow ischemia, performance (DP, RPP and +dP/dt
max
) was less
than in those exposed to hypoxia. EDP and PP were also lower
in low-flow ischemia hearts. The resistance was higher in
low-flow ischemia hearts due to vascular collapse. HR and
–dP/dt
max
 were the same in the two groups.
Figure 3 shows some parameters related to myocardial
metabolism, measured at the same times as those in Fig. 2.
Venous PO
2
 was virtually zero in hypoxic, compared to a
significantly higher value in low-flow ischemia hearts. Nev-
ertheless, the VO
2
 was the same due to different flows in the
two groups. Venous [lactate] was higher during low-flow
ischemia, with lower venous pH, but, for the same reason,
the lactate release was higher in hypoxic than low-flow is-
chemia hearts. The turnover of ATP was higher in hypoxic
than low-flow ischemia hearts.
Figure 4 shows how the duration of low-flow ischemia
or hypoxia affects the recovery of myocardial performance
after reperfusion or reoxygenation. In hearts exposed to
low-flow ischemia and reperfusion, RPP always remained
>90% of the baseline value of 30.3 ± 0.4 mmHg·min–1·10–
3. Varying the duration of low-flow ischemia up to 60 min
did not alter significantly RPP: The slope of the linear re-
gression in the plot RPP vs. the duration of low-flow ischemia
was +0.043 ± 0.023 mmHg·1000·min–2, i.e. not different
from zero (p = N.S.). In contrast, in hearts exposed to hy-
poxia and reoxygenated, %RPP decreased from 86 ± 3% for
20 min hypoxia to 63 ± 5% for 60 min hypoxia. The myo-
cardial depression originated from hypoxia-reoxygenation
was thus sensitive of hypoxia duration: The slope of the
linear regression in the plot RPP vs. the duration of hypoxia
(–0.150 ± 0.029 mmHg·1000·min–2) was less than zero (p
< 0.0001).
The rise in EDP essentially mirrored the decrease in %
RPP. While EDP was essentially preserved for varying du-
ration of low-flow ischemia (slope = +0.024 ± 0.013 mmHg·
min–1, not different from zero), it was increased with hy-
poxia duration (slope = +0.334 ± 0.079 mmHg·min–1, p =
0.0002).
In order to assess independently if myocardial down-regu-
Fig. 4. Recovery of the rate·pressure product and rise of the end-diastolic pressure, as measured at the end of the 20 min reperfusion or reoxygenation. Data
are expressed as a function of the duration of the preceding O2 shortage, low-flow ischemia (empty symbols) or hypoxia (filled symbols) of different dura-
tion, plotted on the X-axis, respectively. The equation of the regression lines is reported in the figure.
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lation during the O
2
 stress, and hence the metabolic state, is
related to recovery, we reconsidered previously published
data that were obtained using the same experimental model.
To rule out variables related to animal donors and slightly
different buffer compositions or perfusion conditions, we
choose to consider only data obtained using the same experi-
mental model as that described above. Fig. 5 shows the cor-
relation between some parameters related to the metabolic
state, measured at the end of either low-flow ischemia or
hypoxia of variable length and severity, and the final recov-
ery of either RPP or EDP. It appears that the tissue contents
of ATP and TANP at the end of the O
2
 stress are statistically
related to %RPP. In contrast, the tissue contents of phospho-
creatine and IMP are not related to recovery. The bottom
panels also show that no correlation exists when consider-
ing either the ATP turnover or the myocardial function at the
Fig. 5. Re-analysis of the studies mentioned in Table 1. Various markers of the cardiac metabolic state during ischemia or hypoxia, measured before the
reperfusion, are reported on the X-axis, while the recovery of rate·pressure (%RPP), measured at the end of the reperfusion and expressed as percent of baseline
value, is reported on the Y-axis. Each panel reports the ANOVA P, and, if p < 0.05, the equation and correlation coefficient of the best fit line. n = 9 for all
but for the ATP turnover (n = 6), because this variable was not measured in [4].
148
end of ischemia. This means that while ATP and TANP have
some predictive value for the functional recovery in this
model, such is not a property of either other metabolic pa-
rameters or of the functional level per se.
Figure 6 shows that the behavior of ∆EDP essentially mir-
rors that of %RPP. The tissue contents of ATP and TANP at
the end of the O
2
 stress are statistically related to ∆EDP. In
contrast, a relationship was absent between rise in EDP and
end-ischemic tissue contents of phosphocreatine and IMP, as
well as ATP turnover and RPP.
Discussion
In this model, increasing the duration of low-flow ischemia
did not induce significant post-reperfusion dysfunction, but
prolongation of hypoxia (same O
2
 shortage) progressively
impaired post-reoxygenation performance. Possibly, low-
flow ischemia induced a situation compatible with adapta-
tion to shortened O
2
 supply, while hypoxia did not induce,
or blunted, adaptation. Evidently, coronary flow differs be-
tween low-flow ischemia and hypoxia, thus a membrane-
Fig. 6. Same as in Fig. 5, but reporting the rise of the end-diastolic pressure over baseline (∆EDP) instead of %RPP on the Y-axis.
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diffusible factor is likely involved. Looking for a possible
explanation, we reconsidered published data obtained in the
same experimental model, finding a negative relationship
between the tissue contents of ATP and TANP during ische-
mia or hypoxia, and the post-reperfusion or reoxygenation
dysfunction. While ATP and TANP belong to a partially dif-
fusible pool of metabolites, phosphocreatine, which is not
related to the post-reperfusion or reoxygenation dysfunction,
belongs to a non-diffusible pool [17].
Critique of the model
The crystalloid-perfused heart model is essentially free from
vascular, neuro-hormonal, inflammatory and blood-mediated
processes. Fixed coronary flows and constant balloon vol-
umes exclude load changes during the experiments. The O
2
supply during the stabilization (12.7 µmoles/min/g) was some-
what higher than that in vivo (8.5–10.1 µmoles/min/g), but
VO
2
 and the high-energy phosphates level compared well to
normal values [3]. The exposure of hearts to low-flow is-
chemia, rather than to global ischemia, allowed hearts to
contract throughout the O
2
 shortage and hence to down-regu-
late performance. The O
2
 shortage during low-flow ischemia
was made equal to that during hypoxia [2]. The ATP turno-
ver allows discrimination between aerobic and anaerobic
components in the bioenergetic apparatus [18]. The recov-
ery is expressed as %RPP and ∆EDP, which represent, respec-
tively, the viability of the contracting mechanism, and the
onset of the diastolic chamber stiffness [19].
Literature
Most of the reports on the relationship between recovery and
ischemia time concern global ischemia [20, 21]. Although one
study suggests the involvement of free radicals [22], other
authors oppose this hypothesis [23–25]. But distinguishing
between low-flow ischemia and global ischemia is important.
For example, some reports show that low-flow ischemia nei-
ther triggers free radical release [26] nor alters the endogenous
pool of scavengers [27]. Indeed, use of free-radical scavengers
does not affect recovery in this model [18]. We are unaware
of other studies comparing dysfunction due to low-flow is-
chemia with that following hypoxia of variable duration.
Myocardial down-regulation
In this model, low-flow ischemia could induce a condition
compatible with adaptation to O
2
 shortage by down-regulat-
ing ATP turnover and functional performance. This adaptation
failed to occur during hypoxia. While the aerobic contribution
(VO
2
) to ATP turnover was the same, the anaerobic contribu-
tion (lactate release) was higher during hypoxia than during
low-flow ischemia. Therefore, hypoxia induced hearts to de-
plete their energy store faster than low-flow ischemia. The
known modulation of phosphofructokinase activity by intrac-
ellular lactate [28] may explain the differential adjustments to
low-flow ischemia and hypoxia. Lactate buildup during low-
flow ischemia inhibits glycolysis, but during hypoxia the in-
hibition is released by the high flow, which removes lactate.
We cannot exclude the occurrence of phenomena such as trans-
mural flow redistribution within the ventricular wall. But the
positive pressure exerted against the ventricle wall by the intra-
ventricular balloon should have minimized flow heterogeneity.
Also, endothelin-1, a powerful vasoconstrictor with growth-
promoting action and an early marker for coronary endothe-
lial dysfunction [29, 30], may play a role in exacerbating the
injury. But lower resistance in hypoxic hearts compared to low-
flow ischemia excludes the occurrence of high shear stress,
which is known to trigger endothelin-1 release.
ATP catabolism and recovery
Down-regulation of the energy need implies preservation of
the ATP pool. Normally, ATP catabolism is compensated by
ATP synthesis from basic precursors [31]. As this rate can be
accelerated only 6 times during anoxia [32], it cannot compete
with increased ATP catabolism as during severe ischemia. This
leads to formation of membrane-diffusible substances, lost
during high-flow conditions with resulting depletion of the
ATP pool [13, 33, 34]. As purine salvage, which is faster than
ATP synthesis rate from basic precursors [35], makes use of
hypoxanthine [36–39], a diffusible compound, we speculate
that the availability of ATP precursors before the reperfusion
is the factor that limits the recovery of the ATP pool and hence
of myocardial performance. Because previous reports are
conflicting (while some confirm the hypothesis [6–8], oth-
ers reject it [9–12]), we reconsidered data obtained in the
same model and using the same methodologies as those de-
scribed here. Although correlation does not imply causation,
the recovery of RPP and the preservation of EDP are corre-
lated to the size of the ATP pool before reperfusion or re-
oxygenation. This observation could not have emerged by
using 31P-NMR techniques, because the diffusible compounds
are invisible to that technique. That relationship is not sig-
nificant when taking the tissue contents of phosphocreatine
and IMP, which are not membrane-diffusible. As ATP turno-
ver and myocardial performance before reperfusion or re-
oxygenation are not related to recovery, we believe that the
protective factor is the availability of the ATP precursors for
purine salvage, and not just the free energy of ATP hydroly-
sis or ∆G
ATP
. Activation of adenosine receptors could also be
involved, even in a rat model [40].
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Clinical implications
Congenital heart malformations with right-to-left intra-car-
diac shunt represent a clinical case related to the present
findings. Our findings indeed may explain in part the higher
mortality and morbidity associated to the surgical treatment
of these diseases with respect to the management of non-
cyanotic hearts, because of blunted down-regulation in hy-
poxic hearts, and greater injury in proportion to the time they
have been hypoxic. In contrast, down-regulation in non-cy-
anotic low-flow ischemic hearts might trigger endogenous
protection mechanisms that induce ischemia tolerance. How-
ever, there are other variables to consider. First, cardiac hyper-
trophy, which might affect to a greater extent hypoxic than
ischemic hearts. Second, acute hypoxic spells, which might
occur more frequently following prolonged periods with low
O
2
 supply. Third, a reduced ventricular performance, com-
parable to down-regulated ischemic hearts in this study,
would not be tolerated in the clinical practice, where a sub-
optimal myocardial performance does not meet the standard
clinical criteria.
Conclusion
The duration of low-flow ischemia does not appreciably in-
fluence recovery in post-ischemic isolated rat hearts, but post-
hypoxic recovery worsens proportionally to hypoxia duration.
While low-flow ischemia induces energy need down-regu-
lation, allowing hearts to spare energy for as long as 60 min
in this model, hypoxia blunts this mechanism. Because post-
ischemic or hypoxic recovery is correlated with the tissue
content of ATP and ATP precursors during the O
2
 shortage,
those features are linked to the preservation of the ATP pool.
Therefore, the contents of ATP and ATP precursors appear
reliable biological markers to predict recovery and good can-
didates to assess the myocardial tolerance to ischemia.
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